Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join our Virtual Triathlon Challenge and swim, cycle and run while raising money to fund Breakthrough T1D’s life-changing type 1 research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Sanofi and Provention Bio partner to support potential launch of drug to delay type 1
Olivier Bogillot, Head of US General Medicines at Sanofi, said: “We are delighted by the prospect of supporting Provention Bio in bringing to the US what could become the first-in-class therapy to change the course of type 1 diabetes. If approved, Sanofi US will leverage its existing world-class capabilities in diabetes care to enhance efforts in both patient and healthcare provider access. We are prepared to tap into all of our internal expertise to support the successful launch of this innovative therapy.”
While Ashleigh Palmer, Co-Founder and Chief Executive Officer at Provention Bio, added: “We look forward to working with our colleagues at Sanofi as we prepare to deliver, if approved, the first-ever disease-modifying therapy for T1D.”
Teplizumab is a promising immunotherapy drug that can protect insulin-producing beta cells from the immune attack that causes type 1 diabetes. It does this by targeting the aggressive immune cells to disarm and kill them.
In doing so, the exciting new drug led to an average three-year delay in the onset of type 1 for people at most risk. This means giving a pre-diabetes patient an extra three years with a functioning pancreas. This remarkable effect is achieved after just 14 days of injections of teplizumab.
Teplizumab is currently under review by the US Food and Drug Administration (FDA) after Provention Bio submitted more evidence in favour of its effectiveness. Sanofi has pledged to invest further in Provention Bio if the FDA does approve teplizumab.
The FDA is expected to announce its decision whether to approve the use of teplizumab in the US later in November.
If the FDA approves teplizumab it will likely influence the decision of international agencies like the Medicines and Healthcare products Regulatory Agency (MHRA), which authorises drugs in the UK.
In summer 2021, teplizimuab was awarded an Innovation Passport by the MHRA. This means that the MHRA has been working closely with Provention Bio to drive teplizimuab towards becoming a licensed treatment in the UK to delay type 1 in those at most risk.
The Innovation Passport and the fast-track it provides was made possible by robust evidence provided by JDRF-funded clinical trials. We are now funding clinical trials as part of the Type 1 Diabetes UK Immunotherapy Consortium to see if teplizumab can also slow the disease progression in people who already have type 1.
Professor David Baker, a Breakthrough T1D-funded researcher at the University of Washington, has been awarded a Nobel Prize in Chemistry.
When given to mice and pigs with type 1 diabetes, a new type of oral insulin developed with JDRF funding detects rising blood glucose and quickly lowers it to a safe level without causing hypos.
Medtronic Diabetes have announced they are funding the biopharmaceutical company Arecor Therapeutics to develop a novel, highly concentrated, thermostable insulin, which will be specialised for use in implantable insulin pumps.
The award recognises Professor Dayan’s remarkable accomplishments in type 1 diabetes research.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.